EP3325487A4 - Préparation pour analogues d'anticholinergiques à potentiel modéré - Google Patents

Préparation pour analogues d'anticholinergiques à potentiel modéré Download PDF

Info

Publication number
EP3325487A4
EP3325487A4 EP16828553.4A EP16828553A EP3325487A4 EP 3325487 A4 EP3325487 A4 EP 3325487A4 EP 16828553 A EP16828553 A EP 16828553A EP 3325487 A4 EP3325487 A4 EP 3325487A4
Authority
EP
European Patent Office
Prior art keywords
formulation
soft anticholinergic
anticholinergic analogs
analogs
soft
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP16828553.4A
Other languages
German (de)
English (en)
Other versions
EP3325487B1 (fr
EP3325487A1 (fr
Inventor
Nicholas S. Bodor
John J. Koleng
David Angulo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bodor Laboratories Inc
Original Assignee
Bodor Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/805,114 external-priority patent/US20150320722A1/en
Application filed by Bodor Laboratories Inc filed Critical Bodor Laboratories Inc
Priority to PL16828553T priority Critical patent/PL3325487T3/pl
Publication of EP3325487A1 publication Critical patent/EP3325487A1/fr
Publication of EP3325487A4 publication Critical patent/EP3325487A4/fr
Application granted granted Critical
Publication of EP3325487B1 publication Critical patent/EP3325487B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
    • A61K8/585—Organosilicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/731—Cellulose; Quaternized cellulose derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/89—Polysiloxanes
    • A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP16828553.4A 2015-07-21 2016-07-21 Préparation pour analogues d'anticholinergiques à potentiel modéré Active EP3325487B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL16828553T PL3325487T3 (pl) 2015-07-21 2016-07-21 Preparat miękkich analogów przeciwcholinergicznych

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/805,114 US20150320722A1 (en) 2014-03-13 2015-07-21 Formulation for soft anticholinergic analogs
PCT/US2016/043380 WO2017015485A1 (fr) 2015-07-21 2016-07-21 Préparation pour analogues d'anticholinergiques à potentiel modéré

Publications (3)

Publication Number Publication Date
EP3325487A1 EP3325487A1 (fr) 2018-05-30
EP3325487A4 true EP3325487A4 (fr) 2019-03-20
EP3325487B1 EP3325487B1 (fr) 2021-05-05

Family

ID=57834721

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16828553.4A Active EP3325487B1 (fr) 2015-07-21 2016-07-21 Préparation pour analogues d'anticholinergiques à potentiel modéré

Country Status (16)

Country Link
US (4) US20180228770A1 (fr)
EP (1) EP3325487B1 (fr)
JP (2) JP6647692B2 (fr)
KR (2) KR20180030893A (fr)
CN (1) CN108137612A (fr)
AU (1) AU2016297601B2 (fr)
CA (2) CA2993602C (fr)
ES (1) ES2881998T3 (fr)
HK (2) HK1251564A1 (fr)
HU (1) HUE055663T2 (fr)
MX (1) MX2018000918A (fr)
MY (1) MY185814A (fr)
PH (1) PH12018500184A1 (fr)
PL (1) PL3325487T3 (fr)
WO (1) WO2017015485A1 (fr)
ZA (1) ZA201800878B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014305778B2 (en) 2013-08-08 2019-11-21 Novan, Inc. Topical compositions and methods of using the same
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
TWI719046B (zh) * 2016-07-21 2021-02-21 美商波德實驗股份有限公司 軟性抗膽鹼類似物之製劑
SG10201912063PA (en) * 2019-12-12 2021-07-29 Nat Skin Centre Singapore Pte Ltd A pharmaceutical formulation
TW202146010A (zh) 2020-03-03 2021-12-16 日商科研製藥股份有限公司 原發性腋窩多汗症的治療方法及其醫藥
CN115175665B (zh) * 2020-03-03 2024-04-16 科研制药株式会社 含有索吡溴铵的药物
FR3124081B1 (fr) * 2021-06-21 2023-12-29 Oreal Composition cosmétique comprenant au moins une huile polaire, un polyol et au moins un actif hydrophile

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014144075A1 (fr) * 2013-03-15 2014-09-18 Bodor Laboratories, Inc. Esters de glycopyrrolate anticholinergiques pour le traitement de l'hyperhidrose

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK149832C (da) * 1981-07-17 1987-05-18 Riemann Claus Antiperspirantpraeparat bestaaende af to komponenter
US5292530A (en) * 1991-06-02 1994-03-08 Helene Curtis, Inc. Stable anhydrous topically-active composition and suspending agent therefor
US5232689A (en) 1990-12-21 1993-08-03 Dow Corning Corporation Translucent antiperspirant compositions
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6433003B1 (en) * 1999-04-23 2002-08-13 Arthur M. Bobrove Method for treating hyperhidrosis in mammals
EP1438001A4 (fr) 2001-09-26 2006-03-15 Alison B Lukacsko Compositions et procedes permettant d'inhiber la sudation eccrine chez l'etre humain
US8252316B2 (en) 2002-05-03 2012-08-28 Purepharm Inc. Method of topically applying glycopyrrolate solution using absorbent pad to reduce sweating
WO2006009986A1 (fr) * 2004-06-23 2006-01-26 Ortho-Mcneil Pharmaceutical, Inc. Procedes de mesure de conductivite de canal chlorure
US20060088496A1 (en) 2004-10-25 2006-04-27 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Personal care compositions with salts of hydroxypropyl trialkylammonium substituted mono-saccharide
GB0428418D0 (en) 2004-12-24 2005-02-02 Novartis Ag Organic compounds
GB0428416D0 (en) 2004-12-24 2005-02-02 Novartis Ag Organic compounds
US8343467B2 (en) * 2004-12-27 2013-01-01 Beiersdorf Ag Glycopyrrolate in cosmetic preparations
JP5257073B2 (ja) * 2005-11-10 2013-08-07 ボーダー、ニコラス・エス ソフト型抗コリン作動性エステル
EP1957451B1 (fr) 2005-11-10 2011-10-19 Nicholas S. Bodor Zwitterions anticholinergiques moderes
US20080023423A1 (en) * 2006-07-31 2008-01-31 James Francis Duffy Device for Holding and Displaying Vial-shaped Beverage Containers
US10265265B2 (en) 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
WO2009051818A1 (fr) 2007-10-18 2009-04-23 Stiefel Research Australia Pty Ltd Formulations topiques de glycopyrrolate
CN103784401A (zh) * 2012-10-29 2014-05-14 北京市丰硕维康技术开发有限责任公司 一种治疗呼吸道疾病的溶液型定量吸入气雾剂及制备方法
CA2919979A1 (fr) 2013-07-30 2015-02-05 Glaxosmithkline Intellectual Property Development Limited Compositions topiques pour le traitement d'une sudation excessive et procede pour les utiliser
US20150259283A1 (en) 2014-03-13 2015-09-17 Brickell Biotech, Inc. Formulation for soft anticholinergic analogs
WO2015138700A1 (fr) 2014-03-13 2015-09-17 Bodor Laboratories, Inc. Utilisation de zwitterions anticholinergiques sélectionnés

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014144075A1 (fr) * 2013-03-15 2014-09-18 Bodor Laboratories, Inc. Esters de glycopyrrolate anticholinergiques pour le traitement de l'hyperhidrose

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Kirk-Othmer Encyclopedia of Chemical Technology", 19 December 2003, JOHN WILEY & SONS, INC., article RAJ SAKAMURI: "ESTERS, ORGANIC", pages: 497 - 526, XP055554355 *

Also Published As

Publication number Publication date
EP3325487B1 (fr) 2021-05-05
EP3325487A1 (fr) 2018-05-30
HK1253236A1 (zh) 2019-06-14
ZA201800878B (en) 2022-08-31
PH12018500184A1 (en) 2018-07-30
BR112018001262A2 (pt) 2018-09-11
WO2017015485A1 (fr) 2017-01-26
JP2020023588A (ja) 2020-02-13
US11026919B2 (en) 2021-06-08
KR20230151061A (ko) 2023-10-31
HUE055663T2 (hu) 2021-12-28
US20180228770A1 (en) 2018-08-16
US20210228544A1 (en) 2021-07-29
US20200121643A1 (en) 2020-04-23
CA3232529A1 (fr) 2017-01-26
AU2016297601B2 (en) 2021-08-19
HK1251564A1 (zh) 2019-02-01
WO2017015485A8 (fr) 2018-02-15
CA2993602A1 (fr) 2017-01-26
AU2016297601A1 (en) 2018-02-15
US10952990B2 (en) 2021-03-23
JP6647692B2 (ja) 2020-02-14
JP2018520198A (ja) 2018-07-26
CA2993602C (fr) 2024-04-30
ES2881998T3 (es) 2021-11-30
KR20180030893A (ko) 2018-03-26
JP6976594B2 (ja) 2021-12-08
MY185814A (en) 2021-06-10
US20210077460A1 (en) 2021-03-18
CN108137612A (zh) 2018-06-08
MX2018000918A (es) 2018-08-15
PL3325487T3 (pl) 2021-12-13

Similar Documents

Publication Publication Date Title
HK1257182A1 (zh) 用於眼部給藥的半氟化的化合物
EP3116498A4 (fr) Préparation pour analogues d'anticholinergiques à potentiel modéré
EP3286169A4 (fr) Nouveaux composés
EP3337502A4 (fr) Formulation anti-ifnar1 stable
EP3295592A4 (fr) Procédures de csi améliorées pour fd-mimo
EP3325449A4 (fr) Composés
EP3368033A4 (fr) Composition thérapeutique à base de miel et de cannabinoïde
EP3332774A4 (fr) Composition pour un enrobage de capsule molle
GB201513010D0 (en) Novel formulation
EP3302439A4 (fr) Composition thérapeutique
HK1253236A1 (zh) 軟性抗膽碱能藥類似物的製劑
ZA201901060B (en) Formulation for soft anticholinergic analogs
EP3210613A4 (fr) Composition pour application externe
EP3373928A4 (fr) Nouvelles formulations
EP3259254A4 (fr) Composés thérapeutiques
EP3355888B8 (fr) Analogues hemi-synthetiques de la trilobine pour utilisation comme medicament
EP3355894A4 (fr) Composition pour le maintien de la dominance de lactobacillus
EP3255044A4 (fr) Composés diaza-benzofluoranthrène
EP3119392A4 (fr) Formulations oculaires
EP3218721A4 (fr) Composés servant d'agents d'imagerie
EP3204347A4 (fr) Composés
EP3295928A4 (fr) Préparation externe pour la peau
EP3345622A4 (fr) Agent servant à renforcer un effet hypotenseur oculaire
EP3325497A4 (fr) Composés quinstatine
EP3562512A4 (fr) Formulation pour la stabilisation d'agents biologiques thérapeutiques

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1251564

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20190220

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/10 20170101ALI20190214BHEP

Ipc: A61K 9/00 20060101AFI20190214BHEP

Ipc: A61K 47/14 20170101ALN20190214BHEP

Ipc: A61K 31/40 20060101ALI20190214BHEP

Ipc: A61K 47/38 20060101ALN20190214BHEP

Ipc: A61K 9/06 20060101ALI20190214BHEP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602016057534

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C07D0491080000

Ipc: A61K0009060000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/24 20060101ALI20201117BHEP

Ipc: A61K 47/38 20060101ALI20201117BHEP

Ipc: A61K 47/12 20060101ALI20201117BHEP

Ipc: A61K 9/06 20060101AFI20201117BHEP

Ipc: A61K 8/34 20060101ALI20201117BHEP

Ipc: A61K 9/08 20060101ALI20201117BHEP

Ipc: A61K 31/40 20060101ALI20201117BHEP

Ipc: A61K 47/10 20170101ALI20201117BHEP

Ipc: A61K 8/58 20060101ALI20201117BHEP

Ipc: A61K 8/891 20060101ALI20201117BHEP

Ipc: A61K 8/49 20060101ALI20201117BHEP

Ipc: A61K 8/37 20060101ALI20201117BHEP

Ipc: C07D 207/12 20060101ALI20201117BHEP

Ipc: A61K 47/14 20170101ALI20201117BHEP

Ipc: A61K 8/73 20060101ALI20201117BHEP

INTG Intention to grant announced

Effective date: 20201203

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KOLENG, JOHN, J.

Inventor name: ANGULO, DAVID

Inventor name: BODOR, NICHOLAS, S.

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1388911

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210515

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016057534

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: FI

Ref legal event code: FGE

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3325487

Country of ref document: PT

Date of ref document: 20210729

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20210726

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20210727

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20210505

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210505

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210505

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210805

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20210402031

Country of ref document: GR

Effective date: 20211013

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210505

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210905

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210505

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2881998

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20211130

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E055663

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210505

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210505

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210505

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210505

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602016057534

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210505

26N No opposition filed

Effective date: 20220208

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210905

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210505

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1388911

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210505

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210505

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230526

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230720

Year of fee payment: 8

Ref country code: NO

Payment date: 20230712

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210505

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20240611

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240530

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20240617

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240613

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240611

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20240618

Year of fee payment: 9

Ref country code: PT

Payment date: 20240627

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20240711

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20240611

Year of fee payment: 9

Ref country code: BE

Payment date: 20240617

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210505

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240612

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240604

Year of fee payment: 9

Ref country code: FI

Payment date: 20240712

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20240712

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240805

Year of fee payment: 9

Ref country code: CH

Payment date: 20240801

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20240704

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20240625

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20240626

Year of fee payment: 9